A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.

NCT00164151 | Completed Phase 3

• 1 other identifier: F38-23
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination.

Conditions

Colonoscopy

Keywords

colonoscopy preparation; prep

Outcome Measures

Primary Outcomes (1)

• Bowel preparation success: preparation rated as "good" or "excellent" by the blinded investigator.

Secondary Outcomes (2)

• Safety: review of preparation symptoms, adverse events and laboratory testing.

• Patient acceptance

Interventions

HalfLytely DRUG

Visicol DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female outpatients who are undergoing colonoscopy for routinely accepted indications, Evaluation of BE results, GI bleeding, Anemia of unknown etiology, Neoplastic disease surveillance, Endosonography, Inflammatory bowel disease (except as noted below), Unknown diarrhea etiology, Polypectomy, Laser therapy, Foreign body removal and decompression (except as noted below).
• years of age or older.
• Otherwise in good health, as determined by physical exam and medical history.
• If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, or vasectomized spouse).
• Subjects with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia must have them corrected prior to study participation.
• Subject has read and signed the written informed consent document prior to study participation.

You may not qualify if:

• Subjects with known or suspected bowel perforation or obstruction, severe inflammatory bowel disease, ileus, acute alimentary tract surgery, significant gastroparesis or gastric outlet obstruction, appendicitis, gastric retention, toxic colitis, toxic megacolon, or massive and/or abnormal rectal bleeding.
• Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
• Subjects with uncontrolled cardiovascular disease.
• Subjects with congestive heart failure.
• Subjects with unstable angina pectoris.
• Subjects with ascites.
• Subjects with renal insufficiency.
• Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
• Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
• Subjects who are pregnant or lactating.
• Subjects who are allergic to polyethyleneglycol.
• Subjects who are allergic to sodium phosphate salts.
• Subjects who are currently taking, or plan to take, other sodium phosphate- containing products, such as enemas or non-prescription liquid purgatives.
• Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics.
• Subjects who are taking drugs that may affect electrolyte levels.

Sponsors & Collaborators

• Braintree Laboratories: lead

Study Sites (1)

Unknown Facility

San Antonio, Texas, 78284, United States

Location

Study Officials

• Charles Brady, MD

  University of Texas Health Science Center San Antonio

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Intervention Model: FACTORIAL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 9, 2005
• First Posted: September 14, 2005
• Study Start: June 1, 2001
• Primary Completion: May 1, 2002
• Last Updated: February 7, 2013

Record last verified: 2013-02

Locations

US (1)